- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03315884
Pilot Randomized Clinical Study of the Iliac Arteries and Common Femoral Artery With Stenting and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery (TASC CD)
Pilot Randomized Clinical Study of the Iliac Arteries and Common Femoral Artery With Stenting Supera and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery Effectiveness in Patients With the Iliac and CFA Segment Occlusive or Stenosis Disease (TASC C, D)
Study Overview
Status
Conditions
Detailed Description
According to the recommendations of the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) statement and the Russian guidelines for limb ischemia treatment (2010), reconstructive surgery is preferred for type D lesions. Patients with type C lesions can be managed by either stenting or bypass surgery. Despite the fact that aorta-femoral reconstructions long-term results are better than the diffuse aorta-iliac lesions endovascular treatment results, the surgery risk is significantly higher than the endovascular surgery risk regarding criteria of mortality, complications, and return to normal activity.
All reports of iliac arteries stenosis percutaneous angioplasty indicate that the primary technical and clinical success rate exceeds 90%. The figure reaches 100% in the case of local lesions. The technical success of iliac arteries long occlusions recanalization reaches 80-85%. Improvement of endovascular equipment designed for the total occlusions treatment increases technical success of recanalization. The TASC II materials summarize the several large studies results which present the data on the operated segment artery patency at the level of 70-81% within 5-8 years of follow up. A large number of authors note the actuality of aortic-iliac type C and D segment lesions endovascular treatment recommendations revision according to the TASC II.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Vyacheslav Mitrofanov
- Phone Number: +79139255543
- Email: v_mitrofanov@meshalkin.ru
Study Locations
-
-
-
Novosibirsk, Russian Federation, 630055
- Recruiting
- NRICP
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with occlusive lesions of C and D type iliac segment and CFA lesion, and with chronic lower limb ischemia (II-IV degree by Fontaine, 4-6 degree by Rutherford), age: 47-75 years old.
- Patients who consented to participate in this study.
Exclusion Criteria:
- Chronic heart failure of III-IV functional class by New York Heart Association (NYHA) classification.
- Decompensated chronic "pulmonary" heart
- Severe hepatic or renal failure (bilirubin> 35 mmol / l, glomerular filtration rate <60 mL / min);
- Polyvalent drug allergy
- Cancer in the terminal stage with a life expectancy less than 6 months;
- Acute ischemic
- Expressed aortic calcification tolerant to angioplasty
- Patient refusal to participate or continue to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Iliac segment recanalization and stenting Iliac segment CFA
Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)
|
Standard access to the CFA is performed.
Outflow ways and CFA capability for reconstruction are determined.
The puncture of the general CFA (retrograde) is performed and the introducer 7Fr. is set.
Recanalization of iliac artery occlusion.
It is necessary to cross the iliac occlusion in a retrograde fashion first and secure aortic inflow before making the arteriotomy.
An ipsilateral, a contralateral and a brachial approaches are used depending on the clinical situation.
If the retrograde access to the aorta failed, you use the antegrade crossing of the iliac occlusion with no intention to reenter the lumen in the CFA.
After the recanalization and balloon angioplasty of iliac artery we completed the procedure with endarterectomy of CFA, patch closure and iliac stenting.
The preference is to perform endarterectomy and patch before iliac stenting because it can be difficult to access the true lumen in a difficult CFA lesion.
Controlling angiography were performed.
Closing approach.
Other Names:
|
Active Comparator: Iliac segment recanalization, stenting and plastic CFA patch
Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch
|
Retrograde femoral access.
Brachial access.
Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized.
Stenosis or artery occlusion is passed with hydrophilic guide.
In case of occlusion transluminal or subintimal (often "mixed") artery recanalization is performed.
To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses.
Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm).
After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter).
In aorta-iliac zone balloon-expandable and self-expandable stents are used.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary patency of the operated segment
Time Frame: during the whole period of observation. Observation is 24 month after surgery
|
during the whole period of observation.
confirmation of patency of the arterial ultrasound of the operated segment.
Confirmation patency of artery 24 months after surgery using Multislice computed tomography angiography of the lower extremities
|
during the whole period of observation. Observation is 24 month after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary patency of the operated artery restenosis
Time Frame: during the whole period of observation. Observation is 24 month after surgery
|
during the whole period of observation.
confirmation of patency of the arterial ultrasound of the operated segment.
Confirmation patency of artery 24 months after surgery using Multislice computed tomography angiography of the lower extremities
|
during the whole period of observation. Observation is 24 month after surgery
|
reocclusion
Time Frame: during the whole period of observation. Observation is 24 month after surgery
|
during the whole period of observation.
confirmation of patency of the arterial ultrasound of the operated segment.
Confirmation patency of artery 24 months after surgery using Multislice computed tomography angiography of the lower extremities
|
during the whole period of observation. Observation is 24 month after surgery
|
postoperative bleeding
Time Frame: in the early postoperative period. Surveillance is 30 days after surgery
|
assessment of bleeding within 30 days after surgery.
The identification of bleeding with physical examination and ultrasound.Considered bleeding requiring surgical intervention
|
in the early postoperative period. Surveillance is 30 days after surgery
|
hematoma
Time Frame: in the early postoperative period. Surveillance is 30 days after surgery
|
in the early postoperative period. Surveillance is 30 days after surgery
|
|
myocardial infarction
Time Frame: during the whole period of observation. Observation is 24 month after surgery
|
during the whole period of observation. Observation is 24 month after surgery
|
|
mortality
Time Frame: during the whole period of observation. Observation is 24 month after surgery
|
during the whole period of observation. Observation is 24 month after surgery
|
|
limb amputation
Time Frame: during the whole period of observation. Observation is 24 month after surgery
|
during the whole period of observation. Observation is 24 month after surgery
|
|
infection
Time Frame: during the whole period of observation. Observation is 24 month after surgery
|
during the whole period of observation. Observation is 24 month after surgery
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NRICP112
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis of the Peripheral Arteries
-
Meshalkin Research Institute of Pathology of CirculationCompletedAtherosclerosis of the Peripheral ArteriesRussian Federation
-
Meshalkin Research Institute of Pathology of CirculationTerminatedСhronic Ischemia of the Lower Extremities | Atherosclerosis of the Tibial Arteries | Lesion no More Than Two Tibial Arteries | Steno-occlusive Lesion of the Tibial ArteriesRussian Federation
-
Boston Scientific CorporationCompletedAtherosclerosis of Native Arteries of the ExtremitiesNew Zealand, United States, Belgium, Canada, Japan, Germany, Austria
-
Boston Scientific CorporationCompletedAtherosclerosis of Native Arteries of the ExtremitiesNew Zealand, Germany, Belgium, Australia, Austria
-
Boston Scientific CorporationCompletedAtherosclerosis of Native Arteries of the Extremities, UnspecifiedBelgium, United States, United Kingdom, Japan, Austria, Canada, Germany
-
Lumen BiomedicalCompleted
-
Jie QiuNational Natural Science Foundation of ChinaCompletedAtherosclerosis of Arteries of the Extremities, Unspecified
-
Centre Hospitalier Universitaire de NīmesCompletedUnilateral vs Bilateral Embolization of the Prostate ArteriesFrance
-
BayerCompletedPeripheral Arterial Disease | Atherosclerosis | Stenotic Femoro-popliteal Arteries | Occluded Femoro-popliteal ArteriesGermany
-
SoundBite Medical Solutions, Inc.ethica Clinical Research Inc.; Prairie Vascular Research Inc.CompletedChronic Total Occlusion of Arteries of the ExtremitiesUnited States, Canada
Clinical Trials on Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch
-
Meshalkin Research Institute of Pathology of CirculationRecruitingAtherosclerosis | Ischemia Limb | Superficial Femoral Artery Occlusion | Popliteal Artery Occlusion | Stent ComplicationRussian Federation
-
Meshalkin Research Institute of Pathology of CirculationUnknownAorta-iliac Segment Lesion (C,D Type by TASC II)Russian Federation